Saturday 17 October 2026
Export ZVSA’s income statement to Excel — free account
ZyVersa Therapeutics, Inc.
ZVSA Healthcare Biotechnology
In the quarter to March 2026, EPS grew 69.9% and free cash flow grew 54.9%, each against the same quarter a year earlier.
0.05
0.00
0.00%
Follow ZVSA
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 817.13% | 1,289.40% | 1,093.82% | (112.65%) |
+8 more TTM periods Free account |
|
| (225.42%) | (236.93%) | (251.13%) | (42.40%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (80.31%) | |
Return on Tangible Assets |
173.38% | 201.45% | 218.31% | 68.29% | |
Free Cash Flow per Share |
(0.51) | (0.86) | (0.76) | (1.06) | |
Free Cash Flow |
(4.14) | (5.11) | (5.92) | (5.12) | |
| Other line items | |||||
Cash ROIC |
29.96% | 41.63% | 52.83% | (83.00%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.05) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(46.85) | (49.66) | (50.52) | (14.91) | |
Operating CF/Net income |
0.17 | 0.21 | 0.23 | 0.62 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.51) | (0.86) | (0.76) | (1.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates